<p>根據 MPM Bioimpact LLC 最近向證券交易委員會（SEC）披露的信息，該公司在第四季度購買了 Vera Therapeutics, Inc.（NASDAQ:VERA - 免費報告）的新頭寸。該基金購買了 257,788 股公司股票，價值約為 10,902,000 美元。截至其最近的 SEC 備案，MPM Bioimpact LLC 持有 Vera Therapeutics 的 0.41%。</p>
<p>獲取 <strong>Vera Therapeutics</strong> 警報：</p>
<p>其他大型投資者最近也對該公司的頭寸進行了調整。Avoro Capital Advisors LLC 在第四季度將其在 Vera Therapeutics 的股份提高了 30.2%。Avoro Capital Advisors LLC 現在擁有 5,610,000 股公司股票，價值 237,247,000 美元，在上個季度又購買了 1,300,410 股。Price T Rowe Associates Inc. MD 在第四季度將其在 Vera Therapeutics 的股份提高了 11.1%。Price T Rowe Associates Inc. MD 現在擁有 4,377,049 股公司股票，價值 185,107,000 美元，在上個季度又收購了 437,940 股。FMR LLC 在第四季度將其在 Vera Therapeutics 的頭寸提高了 9.6%。FMR LLC 現在擁有 3,053,126 股公司股票，價值 129,117,000 美元，在上個季度又購買了 267,842 股。Vanguard Group Inc.在第四季度將其在 Vera Therapeutics 的股份提高了 14.3%。Vanguard Group Inc.現在擁有 2,949,564 股公司股票，價值 124,737,000 美元，在此期間又購買了 369,387 股。最後，Paradigm Biocapital Advisors LP 在第四季度將其在 Vera Therapeutics 的持股提高了 31.0%。Paradigm Biocapital Advisors LP 現在擁有 1,437,339 股公司股票，價值 60,785,000 美元，在上個季度又收購了 340,488 股。目前 99.21% 的股票由機構投資者持有。</p>
<h2>Vera Therapeutics 股票表現</h2>
<p>VERA 股票週三開盤價為 21.58 美元。該公司的市值為 13.8 億美元，市盈率為-8.27，貝塔值為 1.28。公司的債務與股本比率為 0.17，流動比率為 13.76，速動比率為 13.76。Vera Therapeutics, Inc.的 12 個月低點為 18.53 美元，12 個月高點為 51.61 美元。公司的 50 日移動平均價格為 23.92 美元，200 日移動平均價格為 34.43 美元。</p>
<p>Vera Therapeutics（NASDAQ:VERA - 獲取免費報告）最後一次公佈季度財報是在 5 月 8 日星期四。該公司報告每股收益（EPS）為-0.81 美元，低於分析師一致預期的-0.75 美元，差距為 0.06 美元。在去年同期，該公司每股收益為-0.56 美元。研究分析師預計 Vera Therapeutics, Inc.在當前財政年度將發佈-2.89 的每股收益。</p>
<h2>華爾街分析師預測增長</h2>
<p>VERA 已成為多份研究分析師報告的主題。摩根大通將 Vera Therapeutics 的股票目標價從 77.00 美元下調至 71.00 美元，並在 3 月 4 日的報告中給予該股票 “增持” 評級。Guggenheim 將 Vera Therapeutics 的股票目標價從 59.00 美元上調至 61.00 美元，並在 2 月 27 日的研究報告中給予該股票 “買入” 評級。Wolfe Research 在 2 月 4 日的研究報告中開始覆蓋 Vera Therapeutics 的股票。他們給予該股票 “跑贏大盤” 評級，目標價為 49.00 美元。HC Wainwright 在 5 月 5 日的研究報告中開始覆蓋 Vera Therapeutics 的股票。他們給予該股票 “買入” 評級，目標價為 75.00 美元。最後，高盛集團在 1 月 28 日的研究報告中開始覆蓋 Vera Therapeutics 的股票。他們給予該股票 “買入” 評級，目標價為 58.00 美元。一位投資分析師對該股票給予持有評級，七位給予買入評級，兩位給予強烈買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “買入”，共識目標價為 63.33 美元。</p>
<p><strong>查看我們關於 Vera Therapeutics 的最新股票報告</strong></p>
<h2>關於 Vera Therapeutics</h2>
<p>（免費報告）</p>
<p>Vera Therapeutics, Inc.是一家臨牀階段的生物技術公司，專注於開發和商業化針對嚴重免疫疾病患者的治療。其主要產品候選藥物為 atacicept，這是一種以皮下注射方式自我給藥的融合蛋白，目前正在進行針對免疫球蛋白 A 腎病患者的第三階段臨牀試驗；以及針對狼瘡性腎炎的治療，目前正在進行第二階段臨牀試驗。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Vera Therapeutics</li>
<li>股票評級和建議：理解分析師評級</li>
<li>製藥行業拋售：RSI 表示你不應忽視的三隻股票</li>
<li>如何投資生物技術股票</li>
<li>AppLovin 因財報大漲：這家科技公司接下來會怎樣？</li>
<li>股息支付比率計算器</li>
<li>美國監管機構針對 CrowdStrike：這是信號還是噪音？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Vera Therapeutics 嗎？</h2>
<p>在考慮 Vera Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Vera Therapeutics 並不在名單上。</p>
<p>雖然 Vera Therapeutics 目前在分析師中被評為買入，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

VERA

<p>MPM Bioimpact LLC 在 Vera Therapeutics, Inc.（納斯達克代碼：VERA）中獲得了新頭寸，在第四季度購買了 257,788 股，價值約為 1090 萬美元。其他機構投資者，包括 Avoro Capital Advisors 和 Price T Rowe Associates，也增加了對該公司的持股。Vera Therapeutics 的市值為 13.8 億美元，報告的季度每股收益為（$0.81），未達到預期。分析師對該股票的共識評級為 “買入”，平均目標價為 63.33 美元</p>

<p>MPM Bioimpact LLC bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 257,788 shares of the company's stock, valued at approximately $10,902,000. MPM Bioimpact LLC owned 0.41% of Vera Therapeutics as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根據 MPM Bioimpact LLC 最近向證券交易委員會（SEC）披露的信息，該公司在第四季度購買了 Vera Therapeutics, Inc.（NASDAQ:VERA - 免費報告）的新頭寸。該基金購買了 257,788 股公司股票，價值約為 10,902,000 美元。截至其最近的 SEC 備案，MPM Bioimpact LLC 持有 Vera Therapeutics 的 0.41%。</p>
</div><p>Get <strong>Vera Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Vera Therapeutics</strong> 警報：</p>
</div><p>Other large investors have also recently made changes to their positions in the company. Avoro Capital Advisors LLC lifted its stake in shares of Vera Therapeutics by 30.2% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock worth $237,247,000 after buying an additional 1,300,410 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Vera Therapeutics by 11.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,377,049 shares of the company's stock valued at $185,107,000 after acquiring an additional 437,940 shares during the last quarter. FMR LLC lifted its position in Vera Therapeutics by 9.6% in the fourth quarter. FMR LLC now owns 3,053,126 shares of the company's stock worth $129,117,000 after buying an additional 267,842 shares during the last quarter. Vanguard Group Inc. increased its stake in Vera Therapeutics by 14.3% in the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock worth $124,737,000 after purchasing an additional 369,387 shares during the period. Finally, Paradigm Biocapital Advisors LP raised its holdings in shares of Vera Therapeutics by 31.0% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company's stock valued at $60,785,000 after acquiring an additional 340,488 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他大型投資者最近也對該公司的頭寸進行了調整。Avoro Capital Advisors LLC 在第四季度將其在 Vera Therapeutics 的股份提高了 30.2%。Avoro Capital Advisors LLC 現在擁有 5,610,000 股公司股票，價值 237,247,000 美元，在上個季度又購買了 1,300,410 股。Price T Rowe Associates Inc. MD 在第四季度將其在 Vera Therapeutics 的股份提高了 11.1%。Price T Rowe Associates Inc. MD 現在擁有 4,377,049 股公司股票，價值 185,107,000 美元，在上個季度又收購了 437,940 股。FMR LLC 在第四季度將其在 Vera Therapeutics 的頭寸提高了 9.6%。FMR LLC 現在擁有 3,053,126 股公司股票，價值 129,117,000 美元，在上個季度又購買了 267,842 股。Vanguard Group Inc.在第四季度將其在 Vera Therapeutics 的股份提高了 14.3%。Vanguard Group Inc.現在擁有 2,949,564 股公司股票，價值 124,737,000 美元，在此期間又購買了 369,387 股。最後，Paradigm Biocapital Advisors LP 在第四季度將其在 Vera Therapeutics 的持股提高了 31.0%。Paradigm Biocapital Advisors LP 現在擁有 1,437,339 股公司股票，價值 60,785,000 美元，在上個季度又收購了 340,488 股。目前 99.21% 的股票由機構投資者持有。</p>
</div><h2>Vera Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Vera Therapeutics 股票表現</h2>
</div><p>Shares of VERA stock opened at $21.58 on Wednesday. The firm has a market capitalization of $1.38 billion, a P/E ratio of -8.27 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a 12 month low of $18.53 and a 12 month high of $51.61. The company's fifty day moving average price is $23.92 and its two-hundred day moving average price is $34.43.</p>
<div class="lb-trans"><p>VERA 股票週三開盤價為 21.58 美元。該公司的市值為 13.8 億美元，市盈率為-8.27，貝塔值為 1.28。公司的債務與股本比率為 0.17，流動比率為 13.76，速動比率為 13.76。Vera Therapeutics, Inc.的 12 個月低點為 18.53 美元，12 個月高點為 51.61 美元。公司的 50 日移動平均價格為 23.92 美元，200 日移動平均價格為 34.43 美元。</p>
</div><p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same period in the prior year, the business posted ($0.56) earnings per share. On average, research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Vera Therapeutics（NASDAQ:VERA - 獲取免費報告）最後一次公佈季度財報是在 5 月 8 日星期四。該公司報告每股收益（EPS）為-0.81 美元，低於分析師一致預期的-0.75 美元，差距為 0.06 美元。在去年同期，該公司每股收益為-0.56 美元。研究分析師預計 Vera Therapeutics, Inc.在當前財政年度將發佈-2.89 的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>VERA has been the topic of a number of research analyst reports. JPMorgan Chase &amp; Co. dropped their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an &#34;overweight&#34; rating on the stock in a report on Tuesday, March 4th. Guggenheim upped their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, February 27th. Wolfe Research began coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They issued an &#34;outperform&#34; rating and a $49.00 price target on the stock. HC Wainwright started coverage on shares of Vera Therapeutics in a research report on Monday, May 5th. They set a &#34;buy&#34; rating and a $75.00 price target on the stock. Finally, The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a research report on Tuesday, January 28th. They issued a &#34;buy&#34; rating and a $58.00 target price on the stock. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Buy&#34; and a consensus price target of $63.33.</p>
<div class="lb-trans"><p>VERA 已成為多份研究分析師報告的主題。摩根大通將 Vera Therapeutics 的股票目標價從 77.00 美元下調至 71.00 美元，並在 3 月 4 日的報告中給予該股票 “增持” 評級。Guggenheim 將 Vera Therapeutics 的股票目標價從 59.00 美元上調至 61.00 美元，並在 2 月 27 日的研究報告中給予該股票 “買入” 評級。Wolfe Research 在 2 月 4 日的研究報告中開始覆蓋 Vera Therapeutics 的股票。他們給予該股票 “跑贏大盤” 評級，目標價為 49.00 美元。HC Wainwright 在 5 月 5 日的研究報告中開始覆蓋 Vera Therapeutics 的股票。他們給予該股票 “買入” 評級，目標價為 75.00 美元。最後，高盛集團在 1 月 28 日的研究報告中開始覆蓋 Vera Therapeutics 的股票。他們給予該股票 “買入” 評級，目標價為 58.00 美元。一位投資分析師對該股票給予持有評級，七位給予買入評級，兩位給予強烈買入評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 “買入”，共識目標價為 63.33 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Vera Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Vera Therapeutics 的最新股票報告</strong></p>
</div><h2>About Vera Therapeutics</h2>
<div class="lb-trans"><h2>關於 Vera Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.</p>
<div class="lb-trans"><p>Vera Therapeutics, Inc.是一家臨牀階段的生物技術公司，專注於開發和商業化針對嚴重免疫疾病患者的治療。其主要產品候選藥物為 atacicept，這是一種以皮下注射方式自我給藥的融合蛋白，目前正在進行針對免疫球蛋白 A 腎病患者的第三階段臨牀試驗；以及針對狼瘡性腎炎的治療，目前正在進行第二階段臨牀試驗。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Vera Therapeutics</li>
<li>Stock Ratings and Recommendations: Understanding Analyst Ratings</li>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
<li>How to Invest in Biotech Stocks</li>
<li>AppLovin Surges on Earnings: What's Next for This Tech Standout?</li>
<li>Dividend Payout Ratio Calculator</li>
<li>U.S. Regulators Target CrowdStrike: Is It a Signal or Noise?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Vera Therapeutics</li>
<li>股票評級和建議：理解分析師評級</li>
<li>製藥行業拋售：RSI 表示你不應忽視的三隻股票</li>
<li>如何投資生物技術股票</li>
<li>AppLovin 因財報大漲：這家科技公司接下來會怎樣？</li>
<li>股息支付比率計算器</li>
<li>美國監管機構針對 CrowdStrike：這是信號還是噪音？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VERA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Vera Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Vera Therapeutics 嗎？</h2>
</div><p>Before you consider Vera Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Vera Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Vera Therapeutics 並不在名單上。</p>
</div><p>While Vera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Vera Therapeutics 目前在分析師中被評為買入，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

MPM Bioimpact LLC 在 Vera Therapeutics, Inc. (NASDAQ:VERA) 中收購了新的持倉